The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
SITC 2021 | Next steps for cabozantinib plus durvalumab in GI cancer
Anwaar Saeed, MD, University of Kansas Medical Center, Kansas City, MO, discusses the promising future of the combination therapy of cabozantinib plus durvalumab for gastric, esophageal, and colorectal cancer. Dr Saeed proposes that this therapy could be a good option for maintenance or second-line treatment in gastric or esophageal adenocarcinoma, as well as being used post-immunotherapy or front-line for hepatocellular carcinoma. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
